Menu

Pursuing excellence in healthcare

We are pursuing excellence in healthcare by offering best-in-class medical devices and services. We firmly believe in personalized healthcare and it is our vision to provide the best therapeutic solutions tailored to the needs of the individual patient.

About us
210521_Toraymyxin-EAA-homepage_653x337px

Sepsis and septic shock

TORAYMYXIN®

State-of-the-art therapy for patients with endotoxic septic shock

Septic shock is associated with high mortality and a significant economic burden on the sanitary system. Endotoxin is the most potent trigger of the septic cascade and during the progress of sepsis, endotoxin levels can increase up to 1000-fold, even when cultures result negative for Gram-negative bacteria.

Toraymyxin® – Polymyxin B hemoperfusion therapy – from Toray Medical Ltd. (Japan), is the state-of-the-art therapy for endotoxin removal in septic shock patients. More than 200,000 patients have been treated with this innovative therapy and more than 400 peer-reviewed articles have been published, demonstrating the beneficial effects on hemodynamics, organ function, and mortality. Toraymyxin® is now available in two versions: PMX-20R device for patients with adult body volume and PMX-05R device for patients with reduced body volume.

EAA™ – Endotoxin Activity Assay – is the only FDA-approved diagnostic assay to detect endotoxin activity in human whole blood. The EAA™ diagnostic test is performed in less than 30 minutes. EAA™ is the diagnostic assay to identify patients with endotoxic septic shock.

chronic-kidney-disease-653x337

Chronic kidney disease

TORAY PMMA FILTRYZER

A personalized therapy based on the individual needs of each patient

Hemofeel_Web_EN_653x337px

Acute kidney injury

HEMOFEELTM

HEMOFEELTM is a new membrane for continuous renal support made of polymethylmethacrylate, a highly hemo- and biocompatible material designed by TORAY – a global leader in advanced materials.

Focus on

260417_Focus-On_TIGRIS_REV_653x337px
Clinical research

TIGRIS TRIAL RESULTS PUBLISHED

The TIGRIS trial results have been published in The Lancet Respiratory Medicine. In patients with endotoxic septic shock, Polymyxin B Hemoadsorption is associated with a high probability of lower mortality at 28 and 90 days. The Tigris trial shows a clinically meaningful signal of reduced mortality with polymyxin B in patients with ESS, alongside an acceptable safety profile.

260506_Focus-On_Certificati_EN_653x337px
Certifications

ESTOR OBTAINS ISO 13485 CERTIFICATION

ESTOR has obtained ISO 13485 certification, the international reference standard for quality management systems in the medical device sector. This achievement is a concrete recognition of the company’s ongoing commitment to safety, regulatory compliance, and the high performance of its products, further confirming its position as a reliable and innovative partner in the medical field.

250813_Focus-On_TIGRIS_653x337px
Clinical research

TIGRIS TRIAL RESULTS

Positive topline results from the Tigris trial have just been announced. This phase 3 follow-on sponsored study evaluates the use of Polymyxin B Hemoadsorption (“PMX” – Toray Medical Inc, Tokyo) in a randomized clinical trial of adults treated for Endotoxic Septic Shock (ESS) selected using the Endotoxin Activity Assay (EAA – Spectral Medical Inc., Toronto).